This study aims to synthesize fluorinated hyperbranched poly(amido amine)s for the delivery of influenza DNA vaccine. Hyperbranched poly(amido amine)s (HP) were synthesized by using Michael-type polyaddition and then fluorinated to obtain fluorinated polymers (F-HP). The target gene was amplified by designing specific primers to construct the eukaryotic expression plasmid of influenza viral PR8 nucleoprotein (NP) gene as DNA vaccines. Then the polyplexes (F-HP/NP) were prepared by the electrostatic interactions between polymers and plasmid. The results suggested that the molecular weight of HP was 59.7 kDa and polydispersity index (PDI) was 2.67. The fluorine content in F-HP was found to be 20% (w/w). Transmission electron microscopy (TEM) revealed that the polyplexes had spherical shapes with sizes around 100 nm (w/w 5-10) and decreased with increasing w/w ratios. F-HP polyplexes showed improved cell uptake, lysosomal escape and elevated expression levels of NP in vitro than polyplexes based on HP. Finally, the in-vivo immunization by F-HP/NP polyplexes triggered improved CD8⁺ T cell responses. This study suggests that fluorinated hyperbranched poly (amido amine)s represent one of the effective carriers for DNA vaccine delivery. The animal experiments were approved by the Experimental Animal Ethics Committee of Yangzhou University.

In this study the blending process of Qingyan tablets was simplified and simulated, and near infrared spectroscopy was used to monitor the blending process of several raw materials in different particle size systems to explore the influence of particle size on the blending end-point. Five blended batches with different particle sizes were designed in this experiment and the near infrared spectra of the blended samples were collected. Partial least squares regression (PLSR) models of the contents of Platycodonis Radix, Fructus Chebulae, borax, Hanshuishi and microcrystalline cellulose were developed. A quantitative model was applied to determine the blending end-points of three separate batches of blends with different particle sizes. The moving block of standard deviation (MBSD) was used as a qualitative method for determination of the blending end-point. The results show that the smaller the particle size of the materials, the shorter the time to reach the blending end-points, and with more accurate model predictions. In addition, although the MBSD method is convenient and fast without modeling, the results of blending end-point determination were not as accurate as PLSR method. This approach allowed us to determine the blending end-point of Qingyan tablets.

The aim of this study was to identify the anti-inflammatory markers of Zhachong shisanwei pills (ZC-13) and characterize their mechanisms. UPLC/Q-TOF-MS combined with an NF-κB dual fluorescence reporter gene system and NO content detection were utilized to identify the anti-inflammatory bioactive substances in ZC-13. Network pharmacology and bioinformatics methods were used to predict the main targets and pathways of these anti-inflammatory markers, and to verify the main anti-inflammatory pathways of costunolide. Results showed that in ZC-13, four kinds of markers related to NF-κB inhibition were identified: gallic acid, ellagic acid, liquiritin apioside, glycyrrhizic acid, and four kinds of markers related to NO release inhibition were found: gallic acid, liquiritigenin, costunolide, and dehydrocostus lactone. The above components exert anti-inflammatory activities mainly through the regulation of PDK1 (3-phosphoinositide-dependent protein kinase 1), MAPK14 (mitogen-activated protein kinase), GSK3β (glycogen synthase kinase-3β) and other anti-inflammatory-related targets, and further adjust the PI3K-AKT (phosphoinositide 3-kinase- protein kinase B), MAPK, mTOR (mammalian target of rapamycin) pathways. Among them, costunolide can inhibit AKT phosphorylation and NF-κB nuclear transfer. The above results identified the anti-inflammatory markers and possible mechanisms of ZC-13, and provide a theoretical basis for standardizing the clinical application and quality of ZC-13.

Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. At present, there is no specific antiviral drug for this virus, and the main clinical treatment is support and symptomatic treatment. Direct targeting the virus and the host targets are two strategies for the development of antiviral drugs. At present, the research and development of COVID-19 therapeutic drugs has made some progress on both approaches. Here we review potential anti-SARS-CoV-2 drugs to discuss the antiviral mechanisms and potential of these drugs from the perspectives of virus and host. The role of traditional Chinese medicine in the treatment of COVID-19 is discussed along with the prospects for drug treatment strategies of COVID-19.

This study was performed to determine the metabolic profile of a new illicit drug, PX-2, in human liver microsomes. Q Exactive™ HF Quadrupole-Orbitrap LC-MS (LC-QE-HF-Orbitrap-MS) was employed to determine the metabolic sites and pathways of phase Ⅰ and phase Ⅱ metabolism. PX-2 was added to a microsomal incubation model to simulate human hepatic metabolism. The results showed that a total of 18 phase Ⅰ metabolites and 3 glucuronidated phase Ⅱ metabolites were generated, with the main metabolic pathways of phase Ⅰ metabolism including amide hydrolysis, fluoropentyl oxidative defluorination, benzyl hydroxylation, and carbazole ring hydroxylation. Based on the type and sites of metabolism, phase Ⅰ metabolites M1.1 (amide hydrolysis), M4.1 (carbazole cyclic hydroxylation), and M3.1 (oxidative defluorinative hydroxylation) are proposed to be potential poisoning markers. The results of this study provide a basis for identification of related drugs and establishment of testing methods in biological samples.

More and more clinical evidence shows that patients with Coronavirus Disease 2019 (COVID-19) died due to severe complications such as acute respiratory distress syndrome and multiple organ failure due to the aggravation of the disease in the later period, and the main cause of the aggravation is "cytokine storm". There is no specific drug for the treatment of severe COVID-19 patients. Although western medicine can improve some symptoms, it leaves a large sequela, while traditional Chinese medicine plays an important role in this outbreak. In this paper, based on the clinical reported cytokines storm-related indicators, the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) was used to mine and screen the traditional Chinese medicines acting on these cytokines based on the theory of "damp toxin invading the lung". It was found that 19 cytokines, including interleukin-6 (IL-6), tumor necrosis factor α (TNFα), granulocyte-macrophage colony stimulating factor (GM-CSF) and so on, were closely related to COVID-19, and 22 traditional Chinese medicines such as Ephedrae Herba, Glycyrrhizae Radix Et Rhizoma and Lonicerae Japonicae Flos acted on these cytokines, so as to provide certain reference for the reasonable choice of prescription and addition or modification of drugs for COVID-19 patients in the middle and late stage of Chinese medicine clinical treatment.

Acid-sensing ion channel 1a (ASIC1a) is an ammonia-chlorine-sensitive ligand-gated ion channel, and is widely distributed and expressed in the central and peripheral nervous systems. In a physiological environment, cells maintain a stable pH value around 7.0-7.5 through various transport modes of H⁺. During the occurrence of some pathological conditions such as allergic asthma, nephritis, arthritis, enteritis, acute lung injury, and other inflammatory diseases, the anaerobic glycolysis of tissue produces H⁺ accumulation of lactic acid and ATP hydrolysis, resulting in tissue acidification and body fluids. The pH value drops sharply to around 4.0-6.0, which further activates ASIC1a, causing a sharp deterioration of the inflammatory disease. In recent years, targeting ASIC1a may be a potential treatment strategy. This review briefly summarizes the role of ASIC1a in inflammatory diseases and discusses the research progress of ASIC1a in inflammatory diseases.

The injectable recombinant protein of exendin-4 and human serum albumin (HSA), E2HSA, is a long-acting glucagon like-peptide-1 (GLP-1) receptor agonist, which is in clinical research stage now. This study aimed to evaluate the protective effects of E2HSA on mouse islet β cell function in vitro and in vivo. In vitro, the mouse insulinoma cells NIT-1 were used to assay the effects of E2HSA on cell viability and proliferation. Besides, the water soluble cholesterol was adopted to induce cell injury, and then the effects of E2HSA on cell viability and apoptosis, as well as the mechanism, were studied. In vivo, the alloxan-induced hyperglycemic mice were repeatedly administered with E2HSA by subcutaneous injection, and the blood glucose, serum insulin, and content of insulin in islets were measured. All animal experiments were carried out with approval of the Experimental Animal Welfare Ethics Committee of the Institute of Materia Medica (Chinese Academy of Medical Sciences and Peking Union Medical College). The results showed that E2HSA significantly increased the viability of NIT-1 cells and the amount of bromodeoxyuridine (BrdU) incorporated in cells. Besides, the water soluble cholesterol significantly decreased the cell viability and induced apoptosis of NIT-1 cells, but E2HSA significantly reversed the injury of NIT-1 cells. Nevertheless, E2HSA significantly increased the expression of pancreatic duodenal homeobox-1 (PDX-1) and protein kinase B (PKB) of NIT-1 cells after injured by water soluble cholesterol. Furthermore, repeated injections of E2HSA significantly reduced the fasting and non-fasting blood glucose, increased the serum insulin level and raised the insulin content in β cells of alloxan-induced hyperglycemic mice. In conclusion, E2HSA could promote proliferation of NIT-1 cells, inhibit the water soluble cholesterol induced injury and apoptosis, and increase the insulin content in serum and islets of alloxan-induced hyperglycemic mice, suggesting the protective effects on pancreatic islet β cell function.

Huang-Kui-Si-Wu Formula (HKSWF) can reduce the accumulation of uremic toxin p-cresyl sulfate (PCS) and its precursor p-cresol (PC) in a rat model of chronic kidney disease (CKD) and delay the progression of CKD. However, the mechanism by which HKSWF decreases PC accumulation is not clear. This study investigated the effect of HKSWF on PC production in intestinal microbes as well as its mechanism of action. After CKD model rats were given HKSWF by intragastric administration, feces were collected to analyze the gut bacterial composition by 16S rDNA sequencing technology. All procedures were approved by the Institutional Animal Care and Use Committee of the Nanjing University of Chinese Medicine. The results showed that HKSWF inhibited PC production without decreasing the abundance of harmful bacteria. HPLC-UV-FLD was used to detect p-cresol. An in vitro anaerobic culture system was used to study the effect and mechanism of action of HKSWF on PC production in gut bacteria. The results show that food-derived tyrosine (Tyr) could significantly promote PC production in intestinal bacteria, and HKSWF (4000, 400, 40 μg·mL^-1) could dose-dependently inhibit PC production in gut bacteria in vitro. HKSWF inhibited bacterial PC synthesis by two pathways: it decreased the oxidation pathway from 82.83% to 38.87%, and increased the reductive pathway from 17.17% to 61.13%. This result suggests that HKSWF could inhibit PC production by switching tyrosine metabolism from an oxidative pathway to a reductive pathway. Secondly, HKSWF could directly inhibit the oxidative pathway of tyrosine and decrease the decomposition of PHA, thereby inhibiting PC production. These results suggest that HKSWF could inhibit the formation of harmful uremic toxins by modulating the metabolic pathway of PC in gut microbiota and thereby delaying CKD progression.

The rapid development of antibiotic resistance among bacterial pathogens has threatened to take humans back to the "pre-antibiotic era". The New Delhi metallo-β-lactamase (NDM-1) hydrolyzes nearly all β-lactam antibiotics including carbapenems. Bacterial strains carrying blaNDM-1 gene are termed "superbugs" and clinical inhibitors of NDM-1 have not yet been identified. Discovery of novel NDM-1 inhibitors is a challenging but rewarding research area. This review focuses on the structural characteristics and catalytic mechanisms of NDM-1, and comprehensively summarizes the development of NDM-1 inhibitors in order to facilitate the further development of NDM-1 inhibitors.